Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Depreciation & Amortization (CF) (2016 - 2025)

Aethlon Medical (AEMD) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $83864.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Depreciation & Amortization (CF) fell 2.29% year-over-year to $83864.0, compared with a TTM value of $339559.0 through Mar 2025, down 5.43%, and an annual FY2025 reading of $339559.0, down 5.43% over the prior year.
  • Depreciation & Amortization (CF) was $83864.0 for Q1 2025 at Aethlon Medical, roughly flat from $83808.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $91473.0 in Q4 2023 and bottomed at $11164.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $63197.5, with a median of $79542.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) surged 644.52% in 2021, then fell 23.83% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $17673.0 in 2021, then skyrocketed by 342.06% to $78126.0 in 2022, then rose by 17.08% to $91473.0 in 2023, then dropped by 8.38% to $83808.0 in 2024, then increased by 0.07% to $83864.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for AEMD at $83864.0 in Q1 2025, $83808.0 in Q4 2024, and $85827.0 in Q3 2024.